Continuity plan at ANS Biotech

07 Apr 2020

Working from home or on site, all the pieces of the ANS Biotech puzzle stay strongly united and mobilized to pursue to proudly serve you.

NEW OXP model now available

30 Mar 2020

We all need good news... Because good news is welcome, both in good times and bad, we are pleased to announce the launch of a new version of our model of Oxaliplatin-induced cold allodynia.

COVID-19

19 Mar 2020

In the current global health context, ANS Biotech is mobilizing and adapting so as not to stop its support in the services for its Customers. We remain available online and fully mobilized for your projects.

ANS Biotech on the Science Exchange platform

01 Mar 2020

We are pleased to announce that ANS Biotech is now an official registered vendor on the Science Exchange platform! Visit our Provider profile (https://www.scienceexchange.com/labs/ans-biotech) and easily start a collaboration with us!

Welcome to the SNI model

10 Feb 2020

The arrival of the SNI model strengthens the already available offer of services in the field of traumatic neuropathic pain.

ANS Biotech explores pain

06 Dec 2018

On Tuesday the 4th of December 2018, the local newspaper “La Montagne”, had an interview with the CEO, François Caussade. READ THE ARTICLE